A pyrazolyl-quinazoline derivative of Formula I an isomer or a mixture of its enantiomers, diastereomers, as well as geometric isomers, an N-oxide thereof, or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2 or 3; X represents O, S or NR'; wherein R' represents hydrogen, C 1-6 -alkyl, C 3-8 -cycloalkyl or C 3-8 -cycloalkylC 1-6 -alkyl; Y represents C 1-6 -alkyl, amino-C 1-6 -alkyl, C 1-6 -alkyl-amino, C 1-6 -alkyl-amino-C 1-6 -alkyl, hydroxy-C 1-6 -alkyl, C 1-6 -alkoxy-C 1-6 -alkyl, C 2-6 -alkenyl, or a monocyclic or polycyclic, carbocyclic group selected from phenyl, naphthyl, 1,2,3,4-tetrahydro-naphthyl and indanyl or a monocyclic or polycyclic heterocyclic group selected from pyrrolidinyl, piperidinyl, furanyl, thienyl and pyrrolyl, which carbocyclic or heterocyclic groups may optionally be substituted one or more times with substituents selected from the group consisting of C 1-6 -alkyl, amino-C 1-6 -alkyl, C 1-6 -alkyl-amino, C 1-6 -alkyl-amino-C 1-6 -alkyl, hydroxy-C 1-6 -alkyl, C 1-6 -alkoxy-C 1-6 -alkyl, C 3-8 -cycloalkyl, C 3-8 -cycloalkyl-C 1-6 -alkyl, C 2-6 -alkenyl, halo, halo-C 1-6 -alkyl, hydroxy, C 1-6 -alkoxy, halo-C 1-6 -alkoxy, cyano, nitro, amino, methylenedioxy, phenyl and morpholinyl; or when n is 0 and X is NR', Y together with R' and together with the nitrogen to which they are attached form a heterocyclic ring selected from pyrrolidinyl, piperidinyl, piperazinyl, furanyl, thienyl, pyrrolyl and morpholinyl, which heterocyclic ring may optionally be substituted with C 1-6 -alkyl or phenyl; and R 1, R 2 and R 3 independently of each other, represent hydrogen, C 1-6 -alkyl, amino-C 1-6 -alkyl, C 1-6 -alkyl-amino, C 1-6 -alkyl-amino-C 1-6 -alkyl, hydroxy-C 1-6 -alkyl, C 1-6 -alkoxy-C 1-6 -alkyl, C 3-8 -cycloalkyl, C 3-8 -cycloalkyl-C 1-6 -alkyl, C 2-6 -alkenyl, halo, halo-C 1-6 -alkyl, hydroxy, C 1-6 -alkoxy, halo-C 1-6 -alkoxy, C 1-6 -alkoxy-carbonyl, cyano, nitro and amino. n is 0, 1, 2 or 3; X represents O, S or NR'; wherein R' represents hydrogen, C 1-6 -alkyl, C 3-8 -cycloalkyl or C 3-8 -cycloalkylC 1-6 -alkyl; Y represents C 1-6 -alkyl, amino-C 1-6 -alkyl, C 1-6 -alkyl-amino, C 1-6 -alkyl-amino-C 1-6 -alkyl, hydroxy-C 1-6 -alkyl, C 1-6 -alkoxy-C 1-6 -alkyl, C 2-6 -alkenyl, or a monocyclic or polycyclic, carbocyclic group selected from phenyl, naphthyl, 1,2,3,4-tetrahydro-naphthyl and indanyl or a monocyclic or polycyclic heterocyclic group selected from pyrrolidinyl, piperidinyl, furanyl, thienyl and pyrrolyl, which carbocyclic or heterocyclic groups may optionally be substituted one or more times with substituents selected from the group consisting of C 1-6 -alkyl, amino-C 1-6 -alkyl, C 1-6 -alkyl-amino, C 1-6 -alkyl-amino-C 1-6 -alkyl, hydroxy-C 1-6 -alkyl, C 1-6 -alkoxy-C 1-6 -alkyl, C 3-8 -cycloalkyl, C 3-8 -cycloalkyl-C 1-6 -alkyl, C 2-6 -alkenyl, halo, halo-C 1-6 -alkyl, hydroxy, C 1-6 -alkoxy, halo-C 1-6 -alkoxy, cyano, nitro, amino, methylenedioxy, phenyl and morpholinyl; or when n is 0 and X is NR', Y together with R' and together with the nitrogen to which they are attached form a heterocyclic ring selected from pyrrolidinyl, piperidinyl, piperazinyl, furanyl, thienyl, pyrrolyl and morpholinyl, which heterocyclic ring may optionally be substituted with C 1-6 -alkyl or phenyl; and R 1, R 2 and R 3 independently of each other, represent hydrogen, C 1-6 -alkyl, amino-C 1-6 -alkyl, C 1-6 -alkyl-amino, C 1-6 -alkyl-amino-C 1-6 -alkyl, hydroxy-C 1-6 -alkyl, C 1-6 -alkoxy-C 1-6 -alkyl, C 3-8 -cycloalkyl, C 3-8 -cycloalkyl-C 1-6 -alkyl, C 2-6 -alkenyl, halo, halo-C 1-6 -alkyl, hydroxy, C 1-6 -alkoxy, halo-C 1-6 -alkoxy, C 1-6 -alkoxy-carbonyl, cyano, nitro and amino.